

1 **Autoantibodies in COVID-19 correlate with anti-viral** 2 **humoral responses and distinct immune signatures**

3

4 Patrick Taeschler^{1†}, MMed; Carlo Cervia^{1†}, MD; Yves Zurbuchen¹, MMed; Sara Hasler¹;
5 Christian Pou², PhD; Ziyang Tan², MSc; Sarah Adamo¹, MMed; Miro E. Raeber¹, PhD; Esther
6 Bächli³, MD; Alain Rudiger⁴, MD; Melina Stüssi-Helbling⁵, MD; Lars C. Huber⁵, MD; Petter
7 Brodin^{2,6,7}, MD, PhD; Jakob Nilsson¹, MD, PhD; Elsbeth Probst-Müller¹, MD, PhD; and Onur
8 Boyman^{1,8} *, MD

9

10 ¹ Department of Immunology, University Hospital Zurich, Zurich, Switzerland

11 ² Science for Life Laboratory, Department of Women's and Children's Health, Karolinska
12 Institutet, Solna, Sweden

13 ³ Clinic for Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland

14 ⁴ Department of Medicine, Limmattal Hospital, Schlieren, Switzerland

15 ⁵ Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland

16 ⁶ Pediatric Rheumatology, Karolinska University Hospital, Solna, Sweden

17 ⁷ Department of Immunology and Inflammation, Imperial College London, London, United
18 Kingdom

19 ⁸ Faculty of Medicine, University of Zurich, Zurich, Switzerland

20

21 [†] Contributed equally

22

23 * Corresponding author: Onur Boyman, MD, Department of Immunology, University Hospital
24 Zurich, Schmelzbergstrasse 26, 8091 Zurich, Switzerland. E-mail: onur.boyman@uzh.ch;
25 phone: +41 44 255 2069.

26

27 This work was funded by Swiss National Science Foundation grants 310030-172978 and
28 310030-200669 (to OB), 4078P0-198431 (to OB and JN) and NRP78 Implementation
29 Programme (to CC and OB), Digitalization Initiative of the Zurich Higher Education
30 Institutions Rapid-Action Call #2021.1_RAC_ID_34 (to CC), Swiss Academy of Medical
31 Sciences grants 323530-191220 (to CC), 323530-191230 (to YZ) and 323530-177975 (to SA),
32 Forschungskredit Candoc of University of Zurich FK-20-022 (to SA), Young Talents in
33 Clinical Research Project Grant (YTCR 08/20) by the Swiss Academy of Medical Sciences
34 and Bangerter Foundation (to MER), the Clinical Research Priority Program of University of
35 Zurich for CRPP CYTIMM-Z (to OB), the Pandemic Fund of University of Zurich (to OB),
36 and an Innovation Grant of University Hospital Zurich (to OB).

37

38 The authors declare no competing financial interests.

39

40 **Abstract**

41 **Background**

42 Several autoimmune features occur during coronavirus disease 2019 (COVID-19), with
43 possible implications for disease course, immunity, and autoimmune pathology.

44 **Objective**

45 We longitudinally screened for clinically relevant systemic autoantibodies to assess their
46 prevalence, temporal trajectory, and association with immunity, comorbidities, and severity of
47 COVID-19.

48 **Methods**

49 We performed highly sensitive indirect immunofluorescence assays to detect anti-nuclear
50 antibodies (ANA) and anti-neutrophil cytoplasmic antibodies (ANCA), along with serum
51 proteomics and virome-wide serological profiling in a multicentric cohort of 175 COVID-19
52 patients followed-up to one year after infection, eleven vaccinated individuals, and 41
53 unexposed controls.

54 **Results**

55 Compared to healthy controls, similar prevalence and patterns of ANA were present in patients
56 during acute COVID-19 and recovery. However, paired analysis revealed a subgroup of
57 patients with transient presence of certain ANA patterns during acute COVID-19. Furthermore,
58 patients with severe COVID-19 exhibited a high prevalence of ANCA during acute disease.
59 These autoantibodies were quantitatively associated with higher SARS-CoV-2-specific
60 antibody titers in COVID-19 patients and in vaccinated individuals, thus linking autoantibody
61 production to increased antigen-specific humoral responses. Notably, the qualitative breadth of
62 antibodies cross-reactive with other coronaviruses was comparable in ANA-positive and ANA-

63 negative individuals during acute COVID-19. In autoantibody-positive patients,
64 multiparametric characterization demonstrated an inflammatory signature during acute
65 COVID-19 and alterations of the B cell compartment after recovery.

66 **Conclusion**

67 Highly sensitive indirect immunofluorescence assays revealed transient autoantibody
68 production during acute SARS-CoV-2 infection, while the presence of autoantibodies in
69 COVID-19 patients correlated with increased anti-viral humoral immune responses and
70 inflammatory immune signatures.

71

72 Word count: 243

73 Max word count: 250

74 **Key messages**

- 75 - Acute COVID-19 patients exhibit transient autoantibody production, indicating a
- 76 temporary loss of self-tolerance.
- 77 - In COVID-19 patients, the presence of autoantibodies is associated with increased
- 78 anti-viral humoral immune responses and inflammatory immune signatures that
- 79 persist into recovery.

80 **Capsule Summary**

81 Autoantibodies in COVID-19 patients are transient and correlate with increased anti-viral
82 humoral immune responses and an inflammatory immune signature persisting into recovery.

83 **Keywords**

84 SARS-CoV-2, COVID-19, COVID-19 vaccination, Anti-nuclear antibodies, Anti-neutrophil
85 cytoplasmic antibodies, Autoimmunity, Autoantibodies, VirScan

87 **Abbreviations**

88 AC – anti-cell

89 ANA – anti-nuclear antibody

90 ANCA – anti-neutrophil cytoplasmic antibody

91 COVID-19 – coronavirus disease 2019

92 IIF – indirect immunofluorescence

93 SARS-CoV-2 – severe acute respiratory syndrome coronavirus 2

94

95 **Introduction**

96 Acute coronavirus disease 19 (COVID-19) causes a large clinical spectrum, ranging from a
97 mild condition in the majority of cases to fatal disease in 1-2% of subjects (1-3). Several
98 features of acute COVID-19 resemble clinical manifestations of systemic inflammatory and
99 autoimmune diseases, such as fatigue, myalgia, hyperinflammation, thrombosis, and skin
100 rashes (3, 4). Furthermore, COVID-19 may trigger the onset of autoimmune pathology, as
101 reported for Guillain-Barré syndrome, anti-phospholipid syndrome, vasculitis, and
102 multisystem inflammatory syndrome in children (5-9). *Vice versa*, autoimmune phenomena
103 have been connected to the pathogenesis of severe COVID-19. Pre-existing autoantibodies
104 targeting the type I interferon pathway have been found in about 10% of COVID-19 cases with
105 critical disease (10-12).

106 Other acute or chronic viral infections have been associated with autoimmune responses, which
107 have been proposed to arise by molecular mimicry, epitope spreading or bystander activation
108 (13). Various autoantibodies have been described in association with COVID-19, including
109 anti-nuclear antibodies (ANA) (14-20), anti-neutrophil cytoplasmic antibodies (ANCA) (15,
110 16, 21), anti-phospholipid antibodies (5, 8, 14, 17, 19, 22), and antibodies targeting different
111 extracellular antigens (11, 16). While the presence of different autoantibodies has been
112 associated with severe COVID-19 and worse outcome (11, 15, 17-19), it remains unclear to
113 what extent autoantibodies are triggered by acute infection, even though transient
114 autoreactivity and new development of autoantibodies have been suggested in a subgroup of
115 COVID-19 patients (16, 20). Furthermore, several aspects of autoantibodies in COVID-19,
116 including their interplay with virus-specific humoral responses and their durability after acute
117 infection, need further elucidation. In this study, we comprehensively characterized
118 autoantibodies by using highly sensitive indirect immunofluorescence (IIF) assays in a
119 multicentric prospective cohort of 227 individuals.

120

121 **Methods**

122 **Human subjects and patient characteristics**

123 Following written informed consent, adult individuals were recruited for medical history and
124 blood sampling between April 2020 and May 2021. The study was approved by the Cantonal
125 Ethics Committee of Zurich (BASEC #2016-01440). The cohort comprised mild and severe
126 COVID-19 patients, healthy controls, and vaccinated individuals.

127 *COVID-19 patients (Table 1, Table S1)*: 175 patients with reverse transcriptase quantitative
128 polymerase chain reaction (RT-qPCR)-confirmed severe acute respiratory syndrome
129 coronavirus 2 (SARS-CoV-2) infection were included during acute COVID-19 at four
130 hospitals in the Canton of Zurich, Switzerland. COVID-19 was classified for maximum disease
131 severity according to the World Health Organization (WHO) classification criteria into mild
132 disease – including asymptomatic (n = 4), mild illness (n = 93) and mild pneumonia (n = 12) –
133 and severe disease – including severe pneumonia (n = 30) and acute respiratory distress
134 syndrome (ARDS; n = 36) (23). Follow-up visits for medical history and blood collection were
135 conducted approximately six months and one year after symptom onset. Unreachable
136 individuals or those declining further participation were lost to follow-up.

137 *Healthy controls (Table 1)*: 41 participants with negative history of SARS-CoV-2 infection
138 and serology were recruited. Five individuals developed COVID-19 after inclusion and were
139 subsequently allocated to the patient cohort.

140 *Vaccinated individuals (Table S2)*: 11 individuals with a negative history and serology for
141 SARS-CoV-2 infection were sampled once before vaccination, once after the first and twice
142 after the second mRNA vaccination with BNT162b2 (BioNTech-Pfizer).

143

144 **Autoantibody detection**

145 ANA were measured by IIF on HEp-2 cells (Euroimmun) with a cut-off dilution of 1:320.
146 ANCA were measured by IIF on neutrophils fixed by ethanol and formalin (Euroimmun) with
147 a cut-off dilution of 1:40. IIF imaging was performed using a diagnostic, computer-aided
148 microscopy system (Euroimmun). ANA patterns were classified according to the international
149 consensus on ANA patterns anti-cell (AC) nomenclature (24) by blinded trained personnel. For
150 paired analyses of ANA patterns, 129 pairs of IIF pictures at 1:320 dilution were blinded for
151 patient characteristics and sampling timepoint, and examined pairwise by the same observer.
152 Antibodies against myeloperoxidase and proteinase 3 were measured on Phadia™ 250
153 (ThermoFisher Scientific) or on Bioflash® (Werfen) according to manufacturer's instructions.
154

155 **Immunoassays**

156 Immunoassays for immunoglobulin (Ig) subsets, anti-SARS-CoV-2 spike S1-specific IgA and
157 IgG, interleukin (IL)-1 β , IL-2, IL-5, IL-6, IL-10, IL-12, interferon- γ (IFN- γ), soluble IL-2
158 receptor α (sIL-2R α), and tumor necrosis factor α (TNF- α), were performed in accredited
159 laboratories at University Hospital Zurich. Serum Ig subsets were quantified on an Optilite®
160 turbidimeter (The Binding Site Group). S1-specific IgA and IgG were measured by enzyme-
161 linked immunosorbent assays (ELISA) (Euroimmun), as established (25). IL-1 β , IL-2, IL-6,
162 IFN- γ and sIL-2R α were determined by ELISA (R&D Systems) on Opsys Reader™ (Dynex).
163 IL-5, IL-10 and IL-12 were measured by cytometric bead assays (BD Biosciences) on a Navios
164 cytometer (Beckman Coulter). TNF- α was determined with a kit (R&D Systems) using
165 MagPix® (ThermoFisher Scientific).

166

167 **Flow cytometry**

168 As established (26), blood samples were processed and analyzed in accredited laboratories at
169 University Hospital Zurich. Blood samples were lysed with VersaLyse, fixed with IOTest3

170 solution and stained with antibodies (Beckman Coulter; **Table S3**). Absolute cell counts were
171 determined using Flow Set Pro Fluorospheres calibration beads on Navios (Beckman Coulter).

172

173 **Serum proteomics**

174 Serum samples were analyzed by a proximity extension assay-based technology 92-plex
175 inflammation panel (Olink[®]), as established (26-28). Six parameters were excluded because
176 less than 50% of samples showed results above detection limit.

177

178 **Human virome-wide serological profiling**

179 As established (7, 29), serum samples were inactivated, normalized for total IgG concentration,
180 and incubated as duplicates with a bacteriophage library displaying linear, 56 amino acid long
181 viral epitopes. IgG-phage complexes were captured with magnetic beads, lysed and quantified
182 by next-generation sequencing. Blank beads samples were used as negative controls. Reads
183 were mapped to the epitope library with Bowtie2, and counts were obtained using SAMtools.
184 A previously described binning strategy was used to identify positivity for epitopes ((30)), with
185 a minimum z-score of 3.5 for both sample replicates compared to negative controls. Results for
186 a total of 112 different human viruses were included in the further analysis. (**Table S4**),
187 whereas eukaryotes, prokaryotes, non-human viruses and human viruses with no variance or a
188 maximal summed epitope hit count below three were excluded.

189

190 **Statistics**

191 Statistical analyses were performed using R (version 4.1.0). Unless otherwise specified,
192 between-group comparison was performed using two-tailed, non-parametric, unpaired testing
193 (Mann-Whitney U) for numeric variables and odds ratios with Fisher's exact test for categorical
194 variables, with p-values of <0.05 defined as significant. Missing values were omitted. Principal

195 component analyses (PCA) were performed using stats (4.2.0) and factoextra (1.0.7) with
196 scaled, centered variables, and loadings are shown as variable coordinates. Spearman's rank
197 correlation was used for associations of numeric variables. Pairwise protein alignment for 56-
198 amino acid (AA) long peptides with SARS-CoV-2 spike (Uniprot Entry P0DTC2) and
199 nucleoprotein (P0DTC9) was generated using Biostrings (2.60.2), with BLOSUM62
200 substitution matrix and gap opening and extension penalty of -11 and -1, respectively. Data
201 visualization was performed using ggplot2 (version 3.3.5), ggfortify (0.4.12), ggVennDiagram
202 (1.1.4), UpSetR (1.4.0), and corplot (0.90). Horizontal lines in violin plots represent medians.
203 Regression lines represent simple linear regression models.
204

205 **Results**

206 **Presence of systemic autoantibodies during acute COVID-19 and recovery**

207 We performed a comprehensive immunological characterization of 175 individuals with
208 confirmed COVID-19 up to one year after infection (**Fig. 1A** and **Table 1, Table S1**), including
209 autoantibody screening by IIF, serum proteomics and serological profiling. 41 individuals with
210 negative history and serology for SARS-CoV-2 infection were included as controls (**Fig. 1A**
211 and **Table 1**). Furthermore, eleven unexposed individuals were sampled before and after
212 vaccination with BNT162b2 (**Table S2**).

213 Using a highly sensitive IIF screening assay, we detected titers of 1:320 and above in 17 of 41
214 (41.4%) healthy individuals thus testing positive for ANA (**Fig. 1B**). This prevalence of ANA
215 positivity was similar to that in COVID-19 patients during acute disease (48.0%, odds ratio
216 (OR) = 1.30, $p = 0.49$) as well as six months (47.4%, OR = 1.27, $p = 0.59$) and one year after
217 recovery (42.3%, OR = 1.04, $p = 1$) (**Fig. 1C–E**). Most of the observed ANA titers were just
218 above the positivity threshold of 1:320. Interestingly, we observed a trend of higher ANA
219 prevalence in individuals with severe COVID-19 compared to mild disease during acute
220 infection (OR 1.85, $p = 0.061$), which was significantly higher at six months after recovery
221 (OR = 3.81, $p = 0.0015$) (**Fig. 1C** and **D**).

222 Similarly, we used an IIF assay to detect ANCA. ANCA prevalence was similar in mild
223 COVID-19 patients during acute disease (3.6%) compared to healthy individuals (2.4%) (**Fig.**
224 **1F** and **G**). Conversely, we observed a significantly higher ANCA prevalence in severe acute
225 COVID-19 patients (19.7%), both compared to healthy subjects ($p = 0.0082$) and mild COVID-
226 19 cases ($p = 0.0096$) (**Fig. 1F** and **G**), which returned to ranges seen in healthy individuals
227 after six months (5.1%, $p = 0.61$) and one year (14.3%, $p = 0.15$) (**Fig. 1H** and **I**).

228 In several patients, nuclear ANA, cytoplasmic ANA, or ANCA were detected concurrently,
229 particularly during acute COVID-19 (**Fig. 1J–M**). Moreover, ANCA showed a tendency to be

230 more frequent in ANA-positive (14.3%) compared to ANA-negative (5.5%) individuals during
231 acute COVID-19 ($p = 0.06$) (**Fig. 1K**).

232

233 **Characteristics of ANA and ANCA patterns in acute COVID-19**

234 To gain a qualitative appreciation, we classified ANA patterns according to the international
235 consensus on ANA patterns anti-cell (AC) nomenclature (24). ANA patterns were very similar
236 in healthy controls and COVID-19 patients at all three sampling timepoints, and in some
237 participants different patterns were detected concurrently (**Fig. 2A–D, Fig. S1A–D**). The most
238 common nuclear patterns were fine-granular nuclear (AC-4 or AC-4 like) and nucleolar (AC-
239 8, AC-9, and AC-10), whereas the most common cytoplasmic patterns were speckled (AC-19
240 and AC-20) (**Fig. 2E–G**).

241 ANCA patterns observed during acute COVID-19 and follow-up were mostly cytoplasmic
242 (**Fig. 2H**). However, cytoplasmic patterns were atypical and, accordingly, none of the ANCA-
243 positive patients showed positivity for either anti-myeloperoxidase (MPO) or anti-proteinase 3
244 (PR3) antibodies (**Fig. 2I**), suggesting other antigen specificities than commonly found in
245 ANCA-associated vasculitis (31, 32).

246

247 **Temporal trajectory of autoantibodies in individual COVID-19 patients**

248 To appreciate changes in ANA and ANCA on an individual level, we performed paired analysis
249 of all patients that attended at least one follow-up ($n = 116$ at six months and $n = 13$ at one
250 year). For ANA, we observed similar proportions of patients with isolated ANA positivity
251 during acute disease (14.7%) and during follow-up (12.4%) (**Fig. 3A**). However, a trend toward
252 a higher proportion of new ANA development at follow-up visit was evident in patients with
253 severe COVID-19 (20.5%) compared to patients with mild COVID-19 (8.2%) ($OR = 2.84$, $p =$
254 0.054) (**Fig. 3B**). To also account for subtle changes of IIF patterns, we conducted a blinded,

255 paired analysis of IIF images to identify patterns that were transiently present either during
256 acute disease or follow-up. Strikingly, we found transient patterns in 11 of 62 (17.7%) ANA-
257 positive COVID-19 patients during acute disease, with speckled cytoplasmic (AC-19 and 20),
258 nucleolar (AC-8, 9, 10) and mitotic being the most frequent patterns (**Fig. 3C and D**). In stark
259 contrast, only three of 59 (5.1%) ANA-positive individuals presented with a pattern during
260 follow-up that was not present during acute disease, thus demonstrating that transient ANA
261 patterns were significantly more prevalent during acute COVID-19 ($p = 0.045$) (**Fig. 3C**).
262 For ANCA, we observed that of ten patients that tested positive during acute COVID-19, eight
263 were negative during follow-up, whereas only two remained positive (**Fig. 3E**). Furthermore,
264 only one patient newly exhibited positive ANCA at follow-up (**Fig. 3E and F**). Collectively,
265 we found that a subgroup of individuals shows ANA and atypical ANCA production during
266 the acute phase of COVID-19, which usually subsides during follow-up.

267

268 **Virus-specific responses in autoantibody-positive and SARS-CoV-2-vaccinated subjects**

269 To elucidate the influence of autoantibody production during acute infection, we investigated
270 the correlation of autoantibodies with specific humoral immune responses to SARS-CoV-2.
271 We longitudinally assessed SARS-CoV-2 spike 1 (S1)-specific immunoglobulin A (IgA) and
272 IgG titers and found that presence of ANA was associated with higher concentrations of S1-
273 specific antibodies in COVID-19 patients during acute disease, which extended to six months
274 after recovery (**Fig. 4A**). Conversely, one year after recovery, we did not observe any
275 differences (**Fig. S2**). The presence of ANA correlated significantly with S1-specific IgG levels
276 even after accounting for age, disease severity, and sampling timepoint in a multiple linear
277 regression model, which was not the case of S1-specific IgA (**Fig. 4B, Table S5**). Similarly,
278 we found higher S1-specific IgA and a trend toward higher IgG titers in patients that tested
279 positive for ANCA during acute disease (**Fig. 4C**).

280 To elucidate whether autoantibodies were associated with an increased humoral immune
281 response only after natural SARS-CoV-2 infection or also after other antigen-specific immune
282 responses, we measured ANA and S1-specific antibodies in 11 individuals before and after
283 COVID-19 vaccination with BNT162b2 (**Fig. 4D–F, Table S2**). Although a tendency of an
284 increased ANA prevalence following the first vaccine shot was apparent, no significant
285 difference was observed between sampling timepoints (**Fig. 4D**). We observed higher S1-
286 specific IgA in ANA-positive individuals when combining data from two and four weeks after
287 the first vaccine shot, whereas no difference was observed for IgG (**Fig. 4E and F**). In summary,
288 these findings suggest the presence of autoantibodies is associated with increased S1-specific
289 humoral responses following acute COVID-19 up to six months after recovery and following
290 SARS-CoV-2 vaccination.

291

292 **Human virome-wide serological profiling in acute COVID-19**

293 Next, we sought to investigate qualitative aspects of antibody responses during acute COVID-
294 19 with respect to previous anti-viral humoral responses in ANA-positive and ANA-negative
295 individuals. Based on the phage immunoprecipitation sequencing (PhIP-seq) technology
296 (VirScan) (33), we performed human virome-wide serological profiling in 97 acute COVID-
297 19 patients and 18 healthy controls. We assessed the results of antibodies directed to 112
298 different viruses (**Table S4**), with data for a total of 87,890 epitopes, consisting of 56-amino
299 acid (AA)-long, overlapping peptides. The library comprised all six human coronaviruses
300 (HCoV) described before the COVID-19 pandemic, including HCoV-HKU1, HCoV-NL63,
301 HCoV-229E, betacoronavirus 1 (BCoV1, including HCoV-OC43), severe acute respiratory
302 syndrome-related coronavirus (SARS-CoV), and Middle east respiratory syndrome-related
303 coronavirus (MERS-CoV).

304 A multivariate analysis using the summed epitope hits per viral species revealed distinct
305 differences in COVID-19 patients compared to healthy controls, which were particularly
306 pronounced more than one week after symptom onset (**Fig. 5A**). Between-group comparisons
307 of COVID-19 patients and healthy controls revealed a significant difference ($p < 0.005$) of
308 summed epitope hits for eight viral species (**Fig. 5B**). Of these, four enterovirus species were
309 more abundant in healthy controls. Conversely, antibodies targeting cytomegalovirus (CMV)
310 and Pegivirus A, and those directed to SARS-CoV and MERS-CoV were significantly more
311 abundant in COVID-19 patients, whereas antibodies targeting the four common coronaviruses
312 HCoV-HKU1, HCoV-NL63, HCoV-229E, and BCoV1, showed a parallel, but insignificant
313 trend ($p > 0.005$) (**Fig. 5B**). Antibodies directed to all coronavirus species correlated positively
314 with time from symptom onset (**Fig. 5C**), thus indicating production of cross-reactive
315 antibodies during acute COVID-19.

316 To further study antibodies targeting CoVs in acute COVID-19, we evaluated serological
317 profiles on a singular epitope level. We found a significantly higher ($p < 0.05$) proportion of
318 COVID-19 patients tested positive for a total of 18 CoV epitopes compared to healthy controls,
319 of which 16 were in the spike and two in the nucleoprotein (**Fig. 5D, Fig. S3A**). Since healthy
320 individuals tested negative for these but positive for only one epitope (**Fig. 5D and E**), we
321 hypothesized these 18 CoV epitopes enriched in COVID-19 patients were targeted by
322 antibodies newly produced during acute COVID-19 and cross-reactive with shared epitopes of
323 other CoVs. Pairwise protein alignment of these epitopes with corresponding SARS-CoV-2
324 proteins allowed identification of regions of SARS-CoV-2 spike and nucleoprotein targeted by
325 cross-reactive antibodies, comprising two segments (AA positions 777–886 and 1105–1195)
326 of spike S2 domain and one segment of nucleoprotein (AA 140–252), which have been
327 previously identified in COVID-19 patients (34). Patients with severe COVID-19 tested
328 positive for significantly more cross-reactive antibodies than mild disease patients (**Fig. 5E**).

329 However, no significant difference was observed in ANA-positive compared to ANA-negative
330 patients (**Fig. 5F**), although the proportion of ANA-positive patients that tested positive was
331 slightly higher for most cross-reactive epitopes (**Fig. 5G**).

332 To explore potential correlations of ANA with humoral responses against other viruses, we
333 compared seroreactivity against all tested viral epitopes and ANA positivity. Several epitopes
334 were detected more frequently ($p < 0.005$) in ANA-positive, but not in ANA-negative,
335 individuals (**Fig. 5H**). Three of the identified peptides were located on Epstein-Barr virus
336 (EBV) nuclear antigen 2 (EBNA-2), to which ANA-positive participants showed more epitope
337 hits, independent of age (**Fig. S3B**). When combining data of all available epitopes, we found
338 significantly more hits in ANA-positive compared to ANA-negative participants, which was
339 most pronounced at younger age (**Fig. 5I**). Thus, human virome-wide serological profiling in
340 acute COVID-19 revealed antibodies cross-reactive to other coronaviruses, whereas ANA-
341 positive participants producing antibodies to more viral epitopes on a virome wide level.

342

343 **Association of autoantibodies with inflammatory signature during acute COVID-19**

344 Several studies have associated autoantibodies with severe COVID-19 (11, 15, 17-19). Thus,
345 we sought to further characterize ANA-positive and ANA-negative COVID-19 patients during
346 acute disease by proteomics comprising 86 inflammatory markers, cytokine measurements,
347 flow cytometry, clinical history, and routine diagnostic analyses. The proportion of participants
348 with a known autoimmune disease was low in our cohort and indifferent in individuals with or
349 without ANA or ANCA (**Table 2**). We found a higher prevalence of comorbidities in
350 autoantibody-positive patients, including hypertension and heart disease, but no significant sex
351 difference (**Table 2**).

352 A multivariate analysis with 130 variables, including demographic parameters, routine
353 diagnostic measurements, and inflammation markers obtained by proteomics (**Table S6**),

354 allowed for a nearly complete separation of severe COVID-19 patients from healthy
355 individuals, with mild COVID-19 patients exhibiting intermediate characteristics (**Fig. 6A**).
356 Several markers contributing to severe COVID-19 were significantly higher ($p < 0.05$) in
357 ANA-positive than ANA-negative COVID-19 patients, revealing an inflammatory signature
358 associated with severe disease in ANA-positive individuals (**Fig. 6B**). Importantly, ANA-
359 positive COVID-19 patients were older and experienced longer hospitalization (**Fig. 6C**), and
360 many inflammation markers, including C-reactive protein (CRP) and interleukin (IL)-6, were
361 elevated compared to ANA-negative patients (**Fig. 6D**). Furthermore, ANA-positivity was
362 associated with T cell activation as suggested by higher soluble IL-2 receptor alpha (sIL-2R α)
363 serum concentrations and increased proportions of activated CD38⁺ HLA-DR⁺ CD4⁺ and CD8⁺
364 T cells (**Fig. 6E**). Similar trends toward an inflammatory signature were also observed in
365 ANCA-positive individuals during acute COVID-19, although these results were limited due
366 to lower prevalence of ANCA (**Fig. S4A and B**).

367 Finally, we assessed characteristics of ANA-positive and ANA-negative COVID-19 patients
368 at six months after acute disease to identify alterations in the absence of acute inflammation. A
369 multivariate analysis of 43 parameters, including patient characteristics and routine diagnostic
370 measurements, revealed differences comparing ANA-positive and ANA-negative individuals
371 (**Fig. 6F, Table S7**), with several inflammation markers, including IL-6, tumor necrosis factor
372 alpha (TNF- α), and sIL-2R α , being significantly higher in ANA-positive participants (**Fig. 6F**
373 and **G, Table S7**). Interestingly, we also observed differences in Ig subclasses, with
374 significantly higher IgG1 and significantly lower IgM in ANA-positive individuals (**Fig. 6H**).
375 Furthermore, marked changes in B cell subsets were apparent, with higher frequencies of IgD⁺
376 CD27⁻ naïve B cells and lower frequencies of IgD⁺ CD27⁺ non-switched and IgD⁻ CD27⁺
377 switched memory B cells in ANA-positive individuals (**Fig. 6I**). Altogether, in autoantibody-
378 positive COVID-19 patients, we found an inflammatory signature during acute disease

379 resembling alterations found in severe disease and changes in inflammation markers, Ig
380 subclasses, and B cells at six months after recovery.
381

382 **Discussion**

383 Although autoantibodies targeting nuclear, cytoplasmic, and soluble autoantigens following
384 viral infections have been well described (35, 36), their significance has remained ill-defined.
385 In this study, we used highly sensitive assays to detect ANA and ANCA, representing systemic
386 autoantibodies, in patients up to one year after infection with SARS-CoV-2. Firstly, we found
387 transient ANA and ANCA in a subgroup of participants during acute COVID-19. Autoantibody
388 production could result from activation of autoreactive B and T cells recognizing viral epitopes
389 by means of molecular mimicry (37, 38). Alternatively, antigen-independent 'bystander'
390 activation of autoreactive B and T cells by cytokines and other inflammatory mediators could
391 drive autoantibody production (28, 39). Particularly in severe COVID-19, which is associated
392 with early neutrophilia and pronounced neutrophil extracellular trap (NET) formation (40, 41),
393 NETs expose shielded intracellular self-antigens (32, 42, 43), thus causing production of
394 ANCA and ANA. Interestingly, a high prevalence of IgA ANCA has been reported in acute
395 COVID-19 patients showing chilblain-like lesions (21). In our study, all ANCA-positive
396 subjects tested negative for anti-MPO and anti-PR3 antibodies, thus it remains elusive whether
397 these ANCA have pathogenic potential.

398 Secondly, we found distinct features in autoantibody-positive COVID-19 patients during acute
399 disease and recovery. Autoantibodies were associated with prolonged hospitalization and
400 inflammation markers during acute disease, supporting recent findings (11, 15, 17-19, 44, 45).
401 Whereas autoantibodies targeting type I interferons have been linked to severe COVID-19 (10-
402 12, 16), severe COVID-19 could decrease self-tolerance by tissue damage and inflammation,
403 altogether leading to generation of autoantibodies. However, confounding factors should be
404 considered, such as age and comorbidities, affecting prevalence of autoantibodies and risk of
405 severe COVID-19. Following these considerations, we found changes in ANA-positive
406 individuals even six months after acute COVID-19, indicating ongoing low-grade

407 inflammation. Furthermore, we observed alterations of the B cell compartment, including
408 increased naïve and decreased memory B cells, previously associated with pre-symptomatic
409 and early-stage autoimmune diseases (46-48). Differences in total Ig concentrations have been
410 found in autoimmune diseases (49) and patients suffering from post-acute COVID-19
411 syndrome (PACS) (50). Thus, we have previously identified an Ig signature in PACS, including
412 low total IgM, and found clinical risk factors, including increased age and severe disease course
413 (50). Although a direct link to autoantibody development in PACS has not been reported, a
414 misdirected immune response may underly both manifestations.

415 Thirdly, we observed higher S1-specific antibody titers in autoantibody-positive COVID-19
416 patients. Similarly, recent reports found increased anti-viral humoral responses in
417 autoantibody-positive individuals during acute COVID-19, although the interrelation remained
418 unclear (16, 19, 22). Interestingly, following COVID-19 mRNA vaccination in systemic lupus
419 erythematosus (SLE) patients, higher humoral responses positively correlated with anti-
420 dsDNA antibodies (45), supporting our findings of increased S1-specific IgA production in
421 ANA-positive individuals following vaccination. Human virome-wide serological profiling
422 revealed production of cross-reactive antibodies to other coronaviruses during acute COVID-
423 19, particularly in severe disease, consistent with broader humoral immune responses in severe
424 COVID-19 (34). Whereas antibodies targeted similar cross-reactive coronavirus epitopes in
425 ANA-positive and ANA-negative COVID-19 patients, more antibodies targeted EBV antigen
426 EBNA-2 in ANA-positive individuals. Higher humoral responses against EBV have been
427 described in ANA-positive individuals, irrespective of autoimmune disease (51, 52). Also,
428 EBV has been associated with development of ANA and SLE (53). Furthermore, severe acute
429 COVID-19 is characterized by extrafollicular B cell activation (20, 44, 54), which is found in
430 autoimmune disease and associated with activation of autoreactive B cells. This increased
431 response could allow for rapid formation of virus-specific antibody-secreting cells (20),

432 potentially explaining why individuals with autoantibodies exhibit higher humoral responses
433 during acute COVID-19. Whether autoantibody-positive subjects also show increased SARS-
434 CoV-2-specific long-lived T cells responses (55) remains to be investigated.
435 Limitations of this study include the use of highly sensitive IIF assays that yielded a high
436 prevalence of positive results in healthy subjects and COVID-19 patients. Most of the measured
437 ANA titers were at or just above the threshold level, which usually would be considered of
438 irrelevant clinical significance. Moreover, we did not assess the specificity of autoantibodies,
439 but recent studies have shown reactivity to a wide spectrum of autoantigens (11, 16).
440 Altogether, our study shows autoantibodies in COVID-19 appear to be transient and correlate
441 with increased anti-viral humoral immune responses and a distinct immune signature. As
442 questions arise regarding long-term consequences of COVID-19, including the risk of immune
443 dysregulation and autoimmune disease, understanding the mechanisms involved in balancing
444 self-tolerance and protective immune responses become crucial to recognize and manage
445 patients at risk for developing autoimmune diseases.
446

447 **Acknowledgments**

448 We thank the diagnostic laboratories of the University Hospital Zurich, Alessandra Guaita,
449 Claudia Meloni, Jennifer Jörger, Jana Epprecht and Claudia Bachmann for their support, and
450 the members of the Boyman Laboratory for helpful discussions. The study overview graphic
451 was generated with BioRender.com.

452

453 **Author contributions**

454 P.T. contributed to patient recruitment and data collection, analysis and interpretation. C.C.
455 contributed to patient recruitment, data collection and data interpretation. Y.Z., S.H., and S.A.
456 contributed to patient recruitment and data collection. C.P., Z.T., and P.B. contributed to data
457 collection. M.E.R. contributed to patient recruitment and clinical management. E.B., A.R.,
458 M.S.-H., L.C.H., and J.N. contributed to patient recruitment. E.P.-M. contributed to data
459 analysis. O.B. conceived the project and interpreted the data. P.T. and O.B. wrote the
460 manuscript. All authors edited and approved the final draft of the article.

461

462

463 **References**

- 464 1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
465 Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-20.
- 466 2. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing
467 SARS-CoV-2 with SARS-CoV and influenza pandemics. *Lancet Infect Dis*. 2020;20(9):e238-
468 e44.
- 469 3. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
470 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A
471 Review. *JAMA*. 2020;324(8):782-93.
- 472 4. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. *Curr Opin*
473 *Rheumatol*. 2021;33(2):155-62.
- 474 5. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and
475 Antiphospholipid Antibodies in Patients with Covid-19. *N Engl J Med*. 2020;382(17):e38.
- 476 6. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-
477 Barré Syndrome Associated with SARS-CoV-2. *N Engl J Med*. 2020;382(26):2574-6.
- 478 7. Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The
479 Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. *Cell*.
480 2020;183(4):968-81.e7.
- 481 8. Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic
482 autoantibodies in serum from patients hospitalized with COVID-19. *Sci Transl Med*.
483 2020;12(570).
- 484 9. Hsu TY, D'Silva KM, Patel NJ, Fu X, Wallace ZS, Sparks JA. Incident systemic
485 rheumatic disease following COVID-19. *Lancet Rheumatol*. 2021;3(6):e402-e4.
- 486 10. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al.
487 Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science*.
488 2020;370(6515).
- 489 11. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional
490 autoantibodies in patients with COVID-19. *Nature*. 2021;595(7866):283-8.
- 491 12. Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies
492 neutralizing type I IFNs are present in. *Sci Immunol*. 2021;6(62).
- 493 13. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander
494 activation, or viral persistence: infections and autoimmune disease. *Clin Microbiol Rev*.
495 2006;19(1):80-94.
- 496 14. Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K,
497 Kotanidou A, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in
498 severely ill patients with COVID-19. *Ann Rheum Dis*. 2020;79(12):1661-3.
- 499 15. Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-
500 CoV-2 infection as a trigger of autoimmune response. *Clin Transl Sci*. 2021;14(3):898-907.
- 501 16. Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset
502 IgG autoantibodies in hospitalized patients with COVID-19. *Nat Commun*. 2021;12(1):5417.
- 503 17. Pascolini S, Vannini A, Deleonardi G, Ciordinik M, Sensoli A, Carletti I, et al. COVID-
504 19 and Immunological Dysregulation: Can Autoantibodies be Useful? *Clin Transl Sci*.
505 2021;14(2):502-8.
- 506 18. Chang SH, Minn D, Kim YK. Autoantibodies in moderate and critical cases of COVID-
507 19. *Clin Transl Sci*. 2021.
- 508 19. Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH, Fink SL. Prevalence of
509 autoantibody responses in acute coronavirus disease 2019 (COVID-19). *J Transl Autoimmun*.
510 2020;3:100073.

- 511 20. Woodruff MC, Ramonell RP, Saini AS, Haddad NS, Anam FA, Rudolph ME, et al.
512 Relaxed peripheral tolerance drives broad. medRxiv. 2021.
- 513 21. Frumholtz L, Bouaziz JD, Battistella M, Hadjadj J, Chocron R, Bengoufa D, et al. Type
514 I interferon response and vascular alteration in chilblain-like lesions during the COVID-19
515 outbreak. *Br J Dermatol*. 2021.
- 516 22. Emmenegger M, Kumar SS, Emmenegger V, Malinauskas T, Buettner T, Rose L, et al.
517 Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by
518 strength of antibody response against SARS-CoV-2 proteins. *PLoS Pathog*.
519 2021;17(12):e1010118.
- 520 23. WHO. COVID-19 Clinical management: living guidance. World Health Organization
521 (2021), doi: www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.
- 522 24. Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W,
523 Francescantonio PL, et al. Report of the First International Consensus on Standardized
524 Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. *Front Immunol*.
525 2015;6:412.
- 526 25. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al.
527 Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe
528 COVID-19. *J Allergy Clin Immunol*. 2021;147(2):545-57.e9.
- 529 26. Adamo S, Chevrier S, Cervia C, Zurbuchen Y, Raeber ME, Yang L, et al. Profound
530 dysregulation of T cell homeostasis and function in patients with severe COVID-19. *Allergy*.
531 2021;76(9):2866-81.
- 532 27. Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-
533 based proximity extension assays provide sensitive and specific detection of low-abundant
534 proteins in human blood. *Nucleic Acids Res*. 2011;39(15):e102.
- 535 28. Chevrier S, Zurbuchen Y, Cervia C, Adamo S, Raeber ME, de Souza N, et al. A distinct
536 innate immune signature marks progression from mild to severe COVID-19. *Cell Rep Med*.
537 2021;2(1):100166.
- 538 29. Pou C, Nkulikiyimfura D, Henckel E, Olin A, Lakshmikanth T, Mikes J, et al. The
539 repertoire of maternal anti-viral antibodies in human newborns. *Nat Med*. 2019;25(4):591-6.
- 540 30. Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, et al. Measles virus infection
541 diminishes preexisting antibodies that offer protection from other pathogens. *Science*.
542 2019;366(6465):599-606.
- 543 31. Suwanchote S, Rachayon M, Rodsaward P, Wongpiyabovorn J, Deekajorndech T,
544 Wright HL, et al. Anti-neutrophil cytoplasmic antibodies and their clinical significance. *Clin*
545 *Rheumatol*. 2018;37(4):875-84.
- 546 32. Nakazawa D, Kumar S, Desai J, Anders HJ. Neutrophil extracellular traps in tissue
547 pathology. *Histol Histopathol*. 2017;32(3):203-13.
- 548 33. Xu GJ, Kula T, Xu Q, Li MZ, Vernon SD, Ndung'u T, et al. Viral immunology.
549 Comprehensive serological profiling of human populations using a synthetic human virome.
550 *Science*. 2015;348(6239):aaa0698.
- 551 34. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling
552 of COVID-19 patients reveals cross-reactivity and correlates of severity. *Science*.
553 2020;370(6520).
- 554 35. Hansen KE, Arnason J, Bridges AJ. Autoantibodies and common viral illnesses. *Semin*
555 *Arthritis Rheum*. 1998;27(5):263-71.
- 556 36. Spohn G, Arenas-Ramirez N, Bouchaud G, Boyman O. Endogenous polyclonal anti-
557 IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation. *J Allergy*
558 *Clin Immunol*. 2017;139(6):1957-65.e3.

- 559 37. Moody R, Wilson KL, Boer JC, Holien JK, Flanagan KL, Jaworowski A, et al.
560 Predicted B Cell Epitopes Highlight the Potential for COVID-19 to Drive Self-Reactive
561 Immunity. *Frontiers in Bioinformatics*. 2021;1(31).
- 562 38. Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, Ji Macario A,
563 Cappello F. Molecular mimicry may explain multi-organ damage in COVID-19. *Autoimmun*
564 *Rev*. 2020;19(8):102591.
- 565 39. Fajgenbaum DC, June CH. Cytokine Storm. *N Engl J Med*. 2020;383(23):2255-73.
- 566 40. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil
567 extracellular traps in COVID-19. *JCI Insight*. 2020;5(11).
- 568 41. Reusch N, De Domenico E, Bonaguro L, Schulte-Schrepping J, Baßler K, Schultze JL,
569 et al. Neutrophils in COVID-19. *Front Immunol*. 2021;12:652470.
- 570 42. van der Linden M, van den Hoogen LL, Westerlaken GHA, Fritsch-Stork RDE, van
571 Roon JAG, Radstake TRDJ, et al. Neutrophil extracellular trap release is associated with
572 antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome.
573 *Rheumatology (Oxford)*. 2018;57(7):1228-34.
- 574 43. Egholm C, Heeb LEM, Impellizzieri D, Boyman O. The Regulatory Effects of
575 Interleukin-4 Receptor Signaling on Neutrophils in Type 2 Immune Responses. *Front*
576 *Immunol*. 2019;10:2507.
- 577 44. Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al.
578 Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in
579 COVID-19. *Nat Immunol*. 2020;21(12):1506-16.
- 580 45. Izmirlly PM, Kim MY, Samanovic M, Fernandez-Ruiz R, Ohana S, Deonaraine KK, et
581 al. Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-
582 2 Vaccination. *Arthritis Rheumatol*. 2021.
- 583 46. Baglaenko Y, Chang NH, Johnson SR, Hafiz W, Manion K, Ferri D, et al. The presence
584 of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular
585 helper cells similar to those in systemic autoimmune rheumatic disease. *Arthritis Res Ther*.
586 2018;20(1):264.
- 587 47. Zhu L, Yin Z, Ju B, Zhang J, Wang Y, Lv X, et al. Altered frequencies of memory B
588 cells in new-onset systemic lupus erythematosus patients. *Clin Rheumatol*. 2018;37(1):205-12.
- 589 48. Slight-Webb S, Lu R, Ritterhouse LL, Munroe ME, Maecker HT, Fathman CG, et al.
590 Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May
591 Regulate Autoimmunity. *Arthritis Rheumatol*. 2016;68(10):2492-502.
- 592 49. Zhang H, Li P, Wu D, Xu D, Hou Y, Wang Q, et al. Serum IgG subclasses in
593 autoimmune diseases. *Medicine (Baltimore)*. 2015;94(2):e387.
- 594 50. Cervia C, Zurbuchen Y, Taeschler P, Adamo S, Hasler S, Raeber M, et al.
595 Immunoglobulin signature predicts risk of post-acute COVID-19
596 syndrome (2021). Available at SSRN:
597 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3850036 . 2021.
- 598 51. Slight-Webb S, Smith M, Bylinska A, Macwana S, Guthridge C, Lu R, et al.
599 Autoantibody-positive healthy individuals with lower lupus risk display a unique immune
600 endotype. *J Allergy Clin Immunol*. 2020;146(6):1419-33.
- 601 52. Jog NR, Young KA, Munroe ME, Harmon MT, Guthridge JM, Kelly JA, et al.
602 Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus
603 erythematosus in at-risk individuals. *Ann Rheum Dis*. 2019;78(9):1235-41.
- 604 53. Cuomo L, Cirone M, Di Gregorio AO, Vitillo M, Cattivelli M, Magliocca V, et al.
605 Elevated antinuclear antibodies and altered anti-Epstein-Barr virus immune responses. *Virus*
606 *Res*. 2015;195:95-9.

- 607 54. Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. Loss
608 of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. *Cell*.
609 2020;183(1):143-57.e13.
- 610 55. Adamo S, Michler J, Zurbuchen Y, Cervia C, Taeschler P, Raeber ME, et al. Signature
611 of long-lived memory CD8. *Nature*. 2021.
- 612

613 **Table 1. COVID-19 study cohort characteristics.**

		Healthy controls	COVID-19 Acute disease		COVID-19 6-month follow-up	
	Disease severity n (%)	41	Mild	Severe	Mild	Severe
Patient characteristics	Age	32 (28–52)	34 (28–52)	68 (57–78)	36 (29–53)	64 (58–74)
	Days after symptom onset		10 (7–16)	14 (9–27)	194 (185–205)	211 (194–224)
	Sex (female)	24 (58.5%)	54 (49.5%)	27 (40.9%)	40 (51.3%)	14 (35.9%)
	Vaccinated	0	0	0	9 (11.7%)	3 (7.7%)
	Hospitalized	–	20 (18.3%)	66 (100%)	12 (15.6%)	39 (100%)
Laboratory parameters	Lymphocyte count (G/l)	1.80 (1.48–2.33)	1.81 (1.18–2.23) ns	0.76 (0.56–1.10)****	1.96 (1.67–2.37) ns	1.77 (1.48–2.34) ns
	CRP (mg/l)	0.6 (0.4–1.6)	1.3 (0.6–5.3)**	59.2 (32.2–119.0)****	0.6 (0.6–1.3) ns	1.7 (2.2–5.1)**
	TNF- α (ng/l)	8.1 (6.4–10.0)	9.8 (7.6–12)**	16.4 (13.0–20.6)****	9 (6.8–10.9) ns	11.8 (9.3–15.0)****
	IL-6 (ng/l)	0.5 (0–1.1)	1.3 (0.1–4.9)***	19.5 (7.4–57.0)****	0.9 (0–2.1)*	1.6 (0.3–5.3)**
	S1-specific IgA (OD ratio)	0.33 (0.25–0.46)	1.77 (0.73–4.81)****	7.24 (2.52–10.2)****	2.52 (1.54–4.96)****	5.09 (3.12–7.75)****
	S1-specific IgG (OD ratio)	0.20 (0.17–0.25)	0.61 (0.27–2.19)****	5.12 (0.32–9.33)****	2.67 (1.29–5.69)****	6.91 (5.18–8.49)****
Comorbidities	Hypertension (n)	5 (12.2%)	12 (11.0%) ns	38 (57.8%)***	6 (7.8%) ns	21 (53.8%)**
	Diabetes (n)	2 (4.9%)	6 (5.5%) ns	19 (28.8%)*	4 (5.2%) ns	12 (30.7%)**
	Heart disease (n)	1 (2.4%)	6 (5.5%) ns	24 (36.6%)***	2 (2.6%) ns	15 (38.5%)***
	Lung disease (n)	5 (12.2%)	10 (9.2%) ns	12 (18.8%)*	5 (6.5%) ns	11 (28.2%) ns
	Malignancy (n)	1 (2.4%)	3 (2.8%) ns	8 (12.1%)*	3 (3.9%) ns	5 (12.8%) ns
	Kidney disease (n)	0 (0%)	8 (7.3%) ns	17 (25.8%)***	3 (3.9%) ns	10 (25.6%)**
	Autoimmune disease (n)	3 (7.3%)	6 (5.5%) ns	7 (10.6%) ns	6 (7.8%) ns	6 (15.4%) ns

614 Medians and interquartile ranges (in parentheses) are specified for continuous variables, with p-values obtained by Mann-Whitney U test, compared
615 to healthy individuals. Numbers of individuals (n) and percentages of corresponding subgroup (in parentheses) are shown for categorical variables,
616 with p-values calculated by Fisher’s exact test, in comparison to healthy individuals. ns, non-significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001;
617 ****, p < 0.0001. OD, optical density.
618

619 **Table 2. Characteristics of ANA- or ANCA-positive and -negative COVID-19 patients at acute disease or six months after infection.**

		COVID-19 Acute disease			COVID-19 6-month follow-up			
		ANA-negative	ANA-positive	p-value	ANA-negative	ANA-positive	p-value	
ANA								
Patient characteristics	n (%)	91 (52.0%)	84 (48.0%)	–	61 (52.6%)	55 (47.4%)	–	
	Age	38 (30–58)	60.5 (38–73)	***	33(29-47)	61 (45–69)	****	
	Days after symptom onset	11 (7–16)	12 (7–19)	ns	195 (186–206)	204 (183–218)	ns	
	Sex (female)	43 (47.3%)	38 (45.2%)	OR 0.92, ns	29 (47.5%)	25 (45.5%)	OR 0.95, ns	
	Comorbidities	Hypertension	18 (19.7%)	32 (38.1%)	OR 2.48, *	8 (12.1%)	19 (34.5%)	OR 3.39, **
		Diabetes mellitus	12 (13.2%)	13 (15.5%)	OR 1.20, ns	6 (9.8%)	10 (18.2%)	OR 1.99, ns
		Heart disease	9 (9.9%)	21 (25.0%)	OR 3.02, **	1 (1.6%)	16 (29.1%)	OR 23.68, ***
		Lung disease	15 (16.5%)	7 (8.3%)	OR 0.46, ns	9 (14.8%)	7 (12.7%)	OR 0.87, ns
Kidney disease		11 (12.1%)	14 (16.7%)	OR 1.45, ns	2 (3.3%)	11 (20.0%)	OR 7.14, **	
Malignancy		4 (4.4%)	8 (9.5%)	OR 2.28, ns	4 (6.6%)	5 (9.1%)	OR 1.40, ns	
Autoimmune disease		8 (8.7%)	5 (5.9%)	OR 0.66, ns	5 (8.2%)	7 (12.7%)	OR 1.62, ns	
ANCA								
Patient characteristics	n (%)	158 (90.3%)	17 (9.7%)	–	113 (97.4%)	3 (2.6%)	–	
	Age	44 (32–65)	71 (57–80)	***	43 (31–64)	69 (64–70)	–	
	Days after symptom onset	11 (7–16)	11 (9–19)	ns	199 (187–216)	182 (164–212)	–	
	Sex (female)	74 (46.8%)	7 (41.2%)	OR 0.79, ns	52 (46.0%)	1 (33.3%)	–	
	Comorbidities	Hypertension	41 (25.9%)	9 (52.4%)	OR 3.19, *	27 (23.9%)	0 (0%)	–
		Diabetes mellitus	21 (13.2%)	4 (23.5%)	OR 2.00, ns	15 (13.3%)	1 (33.3%)	–
		Heart disease	24 (15.2%)	6 (35.2%)	OR 3.02, ns	16 (14.2%)	1 (33.3%)	–
		Lung disease	21 (13.3%)	1 (5.9%)	OR 0.41, ns	15 (13.3%)	1 (33.3%)	–
Kidney disease		22 (13.9%)	3 (17.6%)	OR 1.32, ns	12 (10.6%)	1 (33.3%)	–	
Malignancy		10 (5.9%)	2 (11.8%)	OR 1.96, ns	8 (7.1%)	1 (33.3%)	–	
Autoimmune disease		12 (7.6%)	1 (5.9%)	OR 0.76, ns	12 (10.6%)	1 (33.3%)	–	

620 For continuous variables, medians and interquartile ranges (in parentheses) are specified, with p-values obtained by Mann-Whitney U test
621 comparing individuals with and without autoantibodies. For categorical variables, numbers of individuals (n) and percentages of the
622 corresponding subgroup (in parentheses) and odds ratios (OR) with p-values indicating significance in Fisher’s exact test are shown. ns, non-
623 significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

624 **Figure legends**

625 **Figure 1. Prevalence of autoantibodies in healthy controls and COVID-19 patients during**
626 **acute disease and follow-up.** (A) Study overview. (B–I) Prevalence of ANA titers (B-E) and
627 ANCA (F-I) in healthy controls (n = 41) and COVID-19 patients during acute disease (n =
628 175), six months (n = 116) and one year (n = 92) after symptom onset. (J–M) Venn diagrams
629 depicting co-occurrence of nuclear ANA, cytoplasmic ANA and ANCA in healthy individuals
630 (J; n = 17), acute COVID-19 patients (K; n = 89) and COVID-19 patients six months (L; n =
631 56) or one year (M; n = 42) after SARS-CoV-2 infection that presented with at least one type
632 of autoantibody. P-values indicate comparison of ANA (B-E) and ANCA (F-I) prevalence
633 between mild and severe COVID-19 patients using Fisher’s exact test.

634 **Figure 2. IIF pattern of autoantibodies in acute and recovered COVID-19. (A–D)**
635 Intersection plots showing counts of the four most prevalent ANA patterns (horizontal bars)
636 and counts of pattern combinations (vertical bars) as indicated by the dot matrix, for healthy
637 controls (A), and COVID-19 patients during acute disease (B), six months (C) and one year
638 after symptom onset (D). (E–G) Example IIF pictures showing the most common nuclear,
639 including fine-granular (E) and nucleolar (F), and cytoplasmic, including speckled (G), ANA
640 patterns observed in the study cohort. All images were recorded at a dilution of 1:320. (H) IIF
641 ANCA patterns observed in ANCA-positive COVID-19 patients during acute disease (n = 17)
642 and six months after recovery (n = 3). (I) Anti-MPO and anti-PR3 antibodies during acute
643 COVID-19 (n = 175) in ANCA-positive and ANCA-negative individuals. Dashed lines
644 indicate diagnostic cut-off values.

645 **Figure 3. Paired longitudinal comparison indicates transient induction of autoantibodies**
646 **in acute COVID-19. (A–B)** Temporal trajectory of ANA titers, including all COVID-19
647 patients with at least one follow-up (n = 129), including six months (n = 116) or one year (n =
648 13) after symptom onset. Colors indicate development of ANA status from acute disease to
649 follow-up. **(C)** Results from blinded, paired IIF picture analysis (n = 129). Patterns that were
650 uniquely observed at one timepoint are colored. The p-value was obtained using Fisher’s exact
651 test comparing the prevalence of ANA-positive patients that presented with unique, transient
652 patterns during acute disease or follow-up. **(D)** Exemplary IIF pictures of three patients
653 exhibiting transient ANA patterns during acute COVID-19, with a transient nucleolar (left),
654 cytoplasmic (middle), or mitotic (right) pattern. All pictures were recorded at a dilution of
655 1:320. **(E–F)** Temporal trajectory of ANCA titers (n = 129). Colors indicate development of
656 ANCA status from acute disease to follow-up.

657 **Figure 4. Presence of autoantibodies is associated with an increased virus-specific**
658 **humoral response after SARS-CoV-2 infection and vaccination. (A–B)** S1-specific IgA and
659 IgG in ANA-positive and ANA-negative COVID-19 patients during acute disease (n = 175)
660 and six months after recovery (n = 104). (B) P-values indicate significance of the correlation
661 of ANA positivity as an independent parameter in a multiple linear regression model
662 accounting for age, disease severity and sampling timepoint (**Table S5**). (C) S1-specific IgA
663 and IgG in ANCA-positive and ANCA-negative COVID-19 patients during acute disease (n =
664 175). (D) ANA prevalence and titers in previously unexposed individuals (n = 11) before and
665 after vaccination with BNT162b2 at indicated timepoints. The p-value was calculated using
666 Chi-squared test of independence. (E) S1-specific IgA and IgG before and after COVID19
667 vaccination (n = 11). Red vertical lines indicate the timepoints of first and second vaccination
668 with BNT162b2. (F) S1-specific IgA and IgG in ANA-positive and ANA-negative participants
669 following COVID-19 vaccination with BNT162b2, combining data from 10-13d after the first
670 (n = 11) and 1-3d after the second (n = 10) vaccination.

671 **Figure 5. Comprehensive serological profiling (VirScan) in ANA-positive and ANA-**
672 **negative individuals during acute COVID-19. (A)** Principal component analysis (PCA)
673 accounting for summed epitope hits of 112 viral species, including data of 18 healthy
674 individuals and 96 acute COVID-19 patients, grouped by timepoint of sample collection after
675 symptom onset. Every dot represents an individual participant. Participant groups are encircled.
676 **(B)** Loadings (variable coordinates) of the PCA depicted in (A), with each viral species shown
677 as individual dot (**Table S4**). Colors indicate participant group with higher mean epitope hits
678 per species. Viral species with a significant mean hits difference ($p < 0.005$) between COVID-
679 19 patients and healthy controls are shown as large dots and annotated with colored font.
680 Insignificantly differing coronaviruses ($p > 0.005$) are shown as crosses and annotated with
681 black font. **(C)** Temporal association of summed epitope hits of six coronaviruses after
682 symptom onset, shown for acute COVID-19 patients ($n = 97$) and healthy controls ($n = 18$).
683 Horizontal bar represents mean of healthy controls. **(D)** Percentage of healthy controls and
684 COVID-19 patients with positive results shown for epitopes of six coronavirus species with a
685 prevalence up to 40%. Significantly enriched epitopes ($p < 0.05$) are colored and shaped
686 according to the corresponding protein. **(E–F)** Summed hits for cross-reactive epitopes,
687 comparing healthy controls and patients with mild and severe COVID-19 (E) or COVID-19
688 patients with or without ANA (F). **(G)** Percentage of ANA-positive and ANA-negative
689 COVID-19 patients with positive results for cross-reactive and non-cross-reactive epitopes of
690 six coronavirus species. Dashed lines mark the significance threshold at $p < 0.05$. **(H)**
691 Percentage of ANA-positive and ANA-negative study participants ($n = 115$) with positive
692 results, shown for all available epitopes. Epitopes with insignificant difference ($p \geq 0.005$) are
693 shown as grey dots, whereas significantly enriched epitopes ($p < 0.005$) are colored. EBV,
694 Epstein-Barr virus; HSV-2, herpes simplex virus 2; VZV, varizella-zoster virus; other, other
695 viruses comprising Aichivirus A and Mamastrovirus 1. **(I)** Summed epitope hits per individual

696 including all available epitopes, comparing ANA-negative and ANA-positive participants (top;
697 n = 115), and as a function of age (bottom).

698 **Figure 6. ANA-positive COVID-19 patients exhibit a pro-inflammatory signature. (A)**
699 PCA accounting for 130 parameters (**Table S6**) including data of healthy controls (n = 28) and
700 acute COVID-19 patients (n = 146). Participants with missing values were excluded from this
701 analysis. 95% confidence ellipses (t-distributed) are shown for healthy controls and severe
702 COVID-19 patients. **(B)** Loadings (variable coordinates) of the PCA depicted in (A), with each
703 parameter shown as an individual dot. Colors indicate the group of COVID-19 patients with
704 higher mean for each parameter, and parameters with significant differences ($p < 0.05$) are
705 represented as large dots and selected parameters are annotated (**Table S6**). **(C–E)** Comparison
706 of ANA-negative and -positive individuals among healthy controls or acute COVID-19
707 patients. **(C)** Patient characteristics, including duration of hospitalization (n = 174) and age (n
708 = 216). **(D)** Inflammation markers, including CRP (n = 209) and IL-6 (n = 215). **(E)** T cell
709 activation, including sIL-2R α (n = 215), and CD38⁺HLA-DR⁺ CD4⁺ (n = 210) and CD8⁺ (n =
710 209) T cells. **(F–G)** PCA **(F)** and loadings **(G)** accounting for 43 parameters (**Table S7**)
711 including data of COVID-19 patients six months after recovery (n = 107). Participants with
712 missing values were excluded from this analysis. **(H–I)** Comparison of ANA-negative and
713 ANA-positive COVID-19 patients six months after recovery. **(H)** Concentration of total Ig
714 subclasses in serum (n = 116). **(I)** Frequency of B cell subsets, including IgD⁺CD27⁻ naïve,
715 IgD⁺CD27⁺ non-switched memory and IgD⁻CD27⁺ switched memory B cells (n = 114).

716 **Supplementary Figures**

717 **Figure S1. ANA patterns in healthy controls and COVID-19 patients during acute disease**

718 **and follow-up. (A–D)** Intersection plots showing the counts of all ANA patterns (horizontal
719 bars) and counts of pattern combinations (vertical bars) as indicated by the dot matrix, as
720 observed in healthy individuals (A; n = 41), acute COVID-19 patients (B; n = 175), and
721 COVID-19 patients six months (C; n = 116) and one year (D; n = 92) after recovery.

722

723 **Figure S2. S1-specific humoral response in ANA-positive and ANA-negative COVID-19**

724 **patients one year after recovery.** S1-specific IgA and IgG in ANA-positive and ANA-
725 negative COVID-19 patients (n = 37).

726

727 **Figure S3. Human virome-wide serological profiling in healthy controls and acute**

728 **COVID-19 patients. (A)** Percentage of healthy controls (n = 18) and COVID-19 patients (n =
729 97) with positive results for all available epitopes of six coronavirus species. Significantly
730 enriched epitopes ($p < 0.05$) are colored and shaped according to the corresponding protein.
731 Dashed lines indicate significance threshold ($p < 0.05$). **(B)** Summed epitope hits of EBNA-2
732 and correlation with age in ANA-negative and -positive participants (n = 115).


733

734 **Figure S4. Multivariate characterization of ANCA-positive and ANCA-negative acute**

735 **COVID-19 patients. (A)** PCA accounting for 130 parameters including data of healthy
736 controls (n = 28) and acute COVID-19 patients (n = 146). Participants with missing values
737 were excluded from this analysis. **(B)** Loadings (variable coordinates) of the PCA depicted in
738 (A), with each parameter shown as an individual dot (**Table S6**). Colors indicate participant


739 group with higher mean, and parameters with significant differences ($p < 0.05$) comparing
740 ANCA-positive and ANCA-negative COVID-19 patients are shown as large dots and
741 annotated.

A




B Healthy controls


ANA titer
 ANA-negative 1:640
 1:320
 >1:640




C Acute COVID-19



D 6-month follow-up




E 1-year follow-up




F Healthy controls


ANCA status
 ANCA-negative
 ANCA-positive




G Acute COVID-19




H 6-month follow-up




I 1-year follow-up




J Healthy controls



K Acute COVID-19



L 6-month follow-up



M 1-year follow-up




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6